Tabaco e morfologia: Doenças pulmonares

Carvalho, Lina

doi:10.1016/S2173-5115(07)70343-3

Article information

Resumo

O tabaco está implicado na carcinogénese multiorgânica, com identificação de mais de cinquenta substâncias carcinogénicas que induzem mutações, alterando o ciclo celular, a resposta auto-imune e a regulação endócrina. É um dos nove factores identificados responsáveis por um terço de mortes por neoplasias malignas juntamente com erros dietéticos, obesidade, sedentarismo, consumo de álcool, promiscuidade sexual, toxicodependência e poluição ambiental geral e limitada. Está implicado nas doenças cardiovasculares que representam a primeira causa de morte nos países civilizados e, no aparelho respiratório, é o factor principal para o desenvolvimento de DPOC (doença pulmonar obstrutiva crónica), RB-ILD (bronquiolite respiratória e doença pulmonar intersticial), DIP (pneumonia intersticial descamativa), bronquiolite e fibrose intersticial bronquiolocêntrica, histiocitose de células de Langerhans, pneumonia eosinofílica, sarcoidose, metaplasia epidermóide do epitélio respiratório e carcinoma bronco-pulmonar. O estado inflamatório crónico sistémico induzido pelo tabaco constitui a base de desenvolvimento de alterações genéticas também dependentes dos contaminantes do tabaco.

Palavras-chave:

Tabaco

morfologia pulmonar

Abstract

Tobacco is implicated in multisystemic carcinogenesis through more than fifty identified carcinogenic metabolites that produce mutations responsible for alterations in cell cycle, immune response and endocrine regulation. Is one of nine risk factors identified in one third of cancer deaths together with obesity, sedentary, alcohol consumption, sexual promiscuity, drug addiction, and open and closed air contamination. Answering for cardiovascular diseases as the first cause of death in civilized world, tobacco is also pointed as the major factor implicated in the development of COPD (chronic obstructive pulmonary disease), RB-ILD (respiratory bronchiolitis and interstitial lung disease), DIP (desquamative interstitial pneumonia), bronchiolitis and bronchiolocentric interstitial fibrosis, Langerhans cells histiocytosis, eosinophilic pneumonia, sarcoidosis, epidermoid metaplasia in respiratory epithelium and lung cancer. The chronic tobacco induced inflammatory state is the basis for the acquisition of genetic alterations dependent on the tobacco contaminants.

Key-words:

Tobacco

lung morphology

Full text is only aviable in PDF

Bibliografia

[1.]

G.C. Kabat.

Fifty years' experience of reduced-tar cigarettes: what do we know about their health effects?.

Inhalation Toxicology, 15 (2003), pp. 1059-1102

http://dx.doi.org/10.1080/08958370390228547 | Medline

[2.]

E. Wynder, E. Graham.

Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma.

Bulletin of the World Health Organization, 83 (2005), pp. 146-153

http://dx.doi.org//S0042-96862005000200016 | Medline

[3.]

N. Godtfredson, E. Prescott, M. Osler.

Effect of smoking reduction on lung cancer risk.

JAMA, 294 (2005), pp. 1505-1510

http://dx.doi.org/10.1001/jama.294.12.1505 | Medline

[4.]

C. Haiman, D. Stram, L. Wilkens, M. Pike, L. Colonel, B. Henderson, L. Marchand.

Ethnic and racial differences in smoking-related risk of lung cancer.

N Engl J Med, 354 (2006), pp. 333-342

http://dx.doi.org/10.1056/NEJMoa033250 | Medline

[5.]

F. Paula, F. Gamito, L. Ferreira.

Importância da nova classificação das pneumonias intersticiais idiopáticas – A propósito de um caso.

Rev Port Pneumol, 7 (2001), pp. 49-56

[6.]

W.D. Travis, T.E. King, E.D. Bateman, et al.

ATS/ERS International Multidisciplinary Consensus Classification of Idiopathic Interstitial Pneumonia.

Am J Respir Crit Care Med, 165 (2002), pp. 277-3304

http://dx.doi.org/10.1164/ajrccm.165.2.ats01 | Medline

[7.]

P.A. Kirkham, G. Spooner, C. Foulkes-Jones, R. Calvez.

Cigarette smoke triggers macrophage adhesion and activation: role of lipid peroxidation products and scavenger receptor.

Free Radical Biology & medicine, 35 (2003), pp. 697-710

http://dx.doi.org/10.1155/2015/762192 | Medline

[8.]

M. Montano, C. Beccerril, V. Ruiz, C. Ramos, R.H. Sansores, G. Gonzalez-Avila.

Matrix metalloproteinases activity in COPD associated with wood smoke.

Chest, 125 (2004), pp. 466-472

Medline

[9.]

S. Nobukuni, K. Watanabe, J. Inoue, F.Q. Wen, N. Tamaru, M. Yoshida.

Cigarette smoke inhibits the growth of lung fibroblasts from patients with pulmonary emphysema.

Respirology, 7 (2002), pp. 217-223

Medline

[10.]

W. Gan, P. Man, D. Sin.

The interactions between cigarette smoking and reduced lung function on systemic inflammation.

Chest, 127 (2005), pp. 558-564

http://dx.doi.org/10.1378/chest.127.2.558 | Medline

[11.]

A.J. Frew.

Advances in environmental and occupational disorders.

Journal of Allergy & Clinical Immunology, 111 (2003), pp. S824-S828

http://dx.doi.org/10.1016/j.jaci.2014.12.1921 | Medline

[12.]

A. Hjern, A. Hedberg, B. Haglung, M. Rosen.

Does tobacco smoke prevent atopic disorders?.

Clinical & Experimental Allergy, 31 (2001), pp. 908-914

http://dx.doi.org/10.1093/femsle/fnu018 | Medline

[13.]

P. Canessa, L. Prattico, L. Bancalari, F. Fedeli, B. Bacigalupi, S. Silvano.

Respiratory bronchiolitis associated with interstitial lung disease.

Monaldi Arch Chest Dis, 61 (2004), pp. 174-176

http://dx.doi.org/10.4081/monaldi.2004.698 | Medline

[14.]

S. Kamholz.

Pulmonary and cardiovascular consequences of smoking.

Clin Occup Environ Med, 5 (2006), pp. 157-171

http://dx.doi.org/10.1016/j.coem.2005.10.001 | Medline

[15.]

E. Grossi, G. Polrtti, V. Poletti.

Acute eosinopholic pneumonia with respiratory failure: a case likely triggered by cigarette smoking.

Monaldi Arch Chest Dis, 61 (2004), pp. 58-61

Medline

[16.]

H. Terasaki, K. Fujimoto, N. Muller, J. Sadohara, M. Uchida, T. Koga, H. Aizawa, N. Havabuchi.

Pulmonary sarcoidosis: comparison of findings of inspiratory and expiratory high-resolution CT and pulmonary function tests between smokers and nonsmokers.

Am J Roentgenol, 185 (2005), pp. 333-338

[17.]

D. Sin, S. Man, A. McWilliams, S. Lam.

Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer.

Am J Respir Crit Care Med, 173 (2006), pp. 535-539

http://dx.doi.org/10.1164/rccm.200508-1305OC | Medline

[18.]

A. Pasic, E. Vliet, R. Breuer, E. Risse, P. Snijders, P. Postmus, T. Sutedja.

Smoking behaviour does not influence the natural course of pre-invasive lesions in bronchial mucosa.

Lung Cancer, 45 (2004), pp. 153-154

http://dx.doi.org/10.1016/j.lungcan.2004.04.029 | Medline

[19.]

K.R. Smith, D.L. Uueminami, U.P. Kodavanti, J.D. Crapo, L.Y. Chang, K.E. Pinkerton.

Inhibition of tobacco smoke-induced lung inflammation by catalytic antioxidant.

Free Radical Biology & Medicine, 33 (2002), pp. 1106-1114

http://dx.doi.org/10.1155/2015/762192 | Medline

[20.]

S.S. Hecht.

Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino(-1-(3- pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen.

Critical Reviews in Toxicology, 26 (1996), pp. 163-181

http://dx.doi.org/10.3109/10408449609017929 | Medline

[21.]

K.A. West, I.R. Linnoila, S.A. BelinsKy, C.C. Harris, P.A. Dennis.

Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidyllinositol 3'-Kinase/Akt pathway in vitro and in vivo.

Cancer Research, 64 (2004), pp. 446-451

Medline

[22.]

H. Adami, D. Hunter, D. Trichopoulos.

Textbook of Cancer Epidemiology.

Oxford University Press, (2002),

[23.]

T. Dutu, S. Michiels, P. Fouret, F. Penault-Llorca, P. Validire, S. Benhamous, E. Taranchon, L. Morat, D. Grunenwald, T. Le Chevalier, L. Sabatier, L. Soria.

Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers.

Ann Oncol, 16 (2005), pp. 1906-1914

http://dx.doi.org/10.1093/annonc/mdi408 | Medline

[24.]

M.G. Traber, A. Vliet, A.Z. Reznick, C.E. Cross.

Tobacco-related diseases.

Clinics in Chest Medicine, 21 (2000), pp. 173-187

Medline

[25.]

J.P. Cooke, H. Bitterman.

Nicotine and angiogenesis: a new paradigm for tobacco-related diseases.

Annals of, 36 (2004), pp. 33-40

[26.]

S.S. Hecht.

Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention.

Lancet Oncology, 3 (2002), pp. 461-469

Medline

[27.]

H. Kuper, H. Adami, P. Boffetta.

Tobacco use, cancer causation and public health impact.

Journal of Internal Medicine, 251 (2002), pp. 455-466

Medline

[28.]

Q. Wei, L. Cheng, C.I. Amos, L.E. Wang, Z. Guo, W.K. Hong, M.R. Spitz.

Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study.

Journal of National Cancer Institute, 92 (2000), pp. 1764-1772

[29.]

H. Kuper, H.O. Adami, P. Boffetta.

Tobacco use, cancer causation and public health impact.

J Intern Med, 251 (2002), pp. 455-466

Medline

[30.]

H.M. Schuller, B.A. Jull, B.J. Sheppard, H.K. Plummer.

Interaction of tobacco-specific toxicants with the neuronal alpha(7) nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders.

European Journal of Pharmacology, 393 (2000), pp. 265-277

Medline

[31.]

J. Wisnivesky, J. Szwarcberg, T. McGinn.

Lung cancer, screening, counselling, and treating long-term smokers.

Geriatrics, 57 (2002), pp. 28-32

Medline

[32.]

Y. Garces, J. Hays.

Tobacco dependence: why should an oncologist care?.

Journal of Clinical Oncology, 21 (2003), pp. 1884-1886

http://dx.doi.org/10.1200/JCO.2003.07.102 | Medline